MA55000A - Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase - Google Patents
Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfataseInfo
- Publication number
- MA55000A MA55000A MA055000A MA55000A MA55000A MA 55000 A MA55000 A MA 55000A MA 055000 A MA055000 A MA 055000A MA 55000 A MA55000 A MA 55000A MA 55000 A MA55000 A MA 55000A
- Authority
- MA
- Morocco
- Prior art keywords
- sulfatase
- heparan
- treatment
- cognitive impairment
- intrathecal administration
- Prior art date
Links
- 208000028698 Cognitive impairment Diseases 0.000 title 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 title 1
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 title 1
- 238000007913 intrathecal administration Methods 0.000 title 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 title 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 title 1
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194695P | 2015-07-20 | 2015-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55000A true MA55000A (fr) | 2022-03-23 |
Family
ID=56561483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055000A MA55000A (fr) | 2015-07-20 | 2016-07-20 | Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10639356B2 (fr) |
| EP (2) | EP3827839B1 (fr) |
| MA (1) | MA55000A (fr) |
| WO (1) | WO2017015375A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| EA201590582A1 (ru) * | 2012-12-07 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения |
-
2016
- 2016-07-20 MA MA055000A patent/MA55000A/fr unknown
- 2016-07-20 US US15/746,192 patent/US10639356B2/en active Active
- 2016-07-20 EP EP20199664.2A patent/EP3827839B1/fr active Active
- 2016-07-20 WO PCT/US2016/043142 patent/WO2017015375A1/fr not_active Ceased
- 2016-07-20 EP EP16745951.0A patent/EP3325000B1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3827839A1 (fr) | 2021-06-02 |
| WO2017015375A1 (fr) | 2017-01-26 |
| US20180207242A1 (en) | 2018-07-26 |
| EP3325000B1 (fr) | 2020-10-21 |
| EP3325000A1 (fr) | 2018-05-30 |
| EP3827839B1 (fr) | 2023-06-21 |
| US10639356B2 (en) | 2020-05-05 |
| EP3827839C0 (fr) | 2023-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283837A (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
| MA43968A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type i | |
| EP3353328A4 (fr) | Modulateurs de l'expression de kras | |
| EP3370721A4 (fr) | Traitement de l'ostéoarthrite | |
| IL257379A (en) | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex | |
| EP3313325A4 (fr) | Échafaudages implantables pour le traitement de la sinusite | |
| EP3013345A4 (fr) | Composés pour le traitement d'une amyotrophie spinale | |
| EP3261641A4 (fr) | Traitement de la pancréatite | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| IL243485A0 (en) | Methods for treating or preventing ophthalmological conditions | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MA44874A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type ii | |
| EP2828247A4 (fr) | Composés pour le traitement de l'amyotrophie spinale | |
| EP2819519A4 (fr) | Composés pour le traitement de l'amyotrophie spinale | |
| EA201790266A1 (ru) | Индолы для применения при инфекции, вызванной вирусом гриппа | |
| MA50016A (fr) | Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i | |
| EP3394758A4 (fr) | Traitement de bloc partiellement écrit | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| EP3386520A4 (fr) | Méthodes de traitement d'une maladie ou d'un trouble oculaire | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| HUE060517T2 (hu) | Immunhiányos betegség kezelésére szolgáló eljárások | |
| MA47847A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type i | |
| LT3307267T (lt) | Išsėtinės sklerozės gydymas | |
| EP2959903A4 (fr) | Médicament pour le traitement de maladie des yeux | |
| PL3487491T3 (pl) | Kompozycje do zwiększenia aktywności mózgu |